greeksoup/ stock research

Rapid Micro Biosystems, Inc.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 7 August 2026: press release. Guidance figures: 1 raised, 3 kept. The quarter’s numbers.

Key takeaways

  • Revenue grew 11% year-over-year: Total revenue was $8.1 million against $7.3 million a year earlier, an increase of 10.9%. Source
  • Consumables grew over 20%: Consumable revenue increased more than 20% year-over-year. Management said consumables reached quarterly records in both units and revenue. Source
  • Four placements and nine validations: Four Growth Direct systems were placed and nine customer systems validated, against four placements and two validations in the second quarter of 2025. Source
  • Operating expenses rose 8.9%: Total operating expenses were $13.5 million, against $12.4 million a year earlier. Source
  • Gross margin reached 15.0%: Gross margin was $1.2 million, or 15.0%, against $0.3 million or 3.8% a year earlier. The release calls it a quarterly record. Source
  • Cash and investments near $20 million: Cash, equivalents and short-term investments were about $20 million at June 30, down from about $23 million at March 31, a figure that included restricted cash. Source
  • Collaboration contribution expected to grow: Management said the MilliporeSigma collaboration is expected to make an expanding contribution in the second half of 2026. Source

“Our second quarter results reflect continued execution against the strategic and financial priorities we outlined at the beginning of the year,”

Robert Spignesi, President and CEO

Guidance

AreaPeriodFigureAgainst last quarter
Total revenue SourceFull year 2026$37.0 million to $41.0 millionKept
Growth Direct system placements SourceFull year 202630 to 38Kept
Gross margin percentage SourceFull year 2026approximately 20%Kept
Gross margin percentage SourceSecond half 2026mid-20% range
System validations SourceFull year 2026at least 27Raised from at least 25

What changed from last quarter

  • Guidance raised: System validation guidance raised to at least 27 from at least 25. Source
  • Guidance kept: Total revenue and placement guidance ranges unchanged from the first-quarter release. Source
  • New: European Growth Direct Day with MilliporeSigma announced for October 2026. Source

Results and growth drivers

  • Revenue grew 11% year-over-year: Total revenue was $8.1 million against $7.3 million a year earlier, an increase of 10.9%. Source
  • Six-month revenue rose 11%: Six-month total revenue was $16.1 million against $14.5 million in the first half of 2025. Source
  • Recurring revenue grew 14%: Recurring revenue was $5.0 million, up 14.3% from $4.4 million in the second quarter of 2025. Source
  • Net loss rose to $12.9 million: Net loss was $12.9 million, or $0.27 per share, against $11.9 million and $0.27 per share a year earlier. Source
  • Adjusted EBITDA loss slightly larger: Non-GAAP adjusted EBITDA loss was $10.3 million against $10.1 million a year earlier. Source

Product and service revenue

  • Product revenue rose 10.1%: Product revenue was $5.3 million, against $4.8 million in the second quarter of 2025. Source
  • Service revenue rose 12.5%: Service revenue was $2.8 million, against $2.5 million a year earlier. Source
  • Consumables grew over 20%: Consumable revenue increased more than 20% year-over-year. Management said consumables reached quarterly records in both units and revenue. Source

“Importantly, we delivered record second-quarter total gross margin of 15%, marking a positive inflection that reflects meaningful progress against our margin expansion initiatives and supports our path to positive cash flow.”

Robert Spignesi, President and CEO

Placements, validations and demand

  • Four placements and nine validations: Four Growth Direct systems were placed and nine customer systems validated, against four placements and two validations in the second quarter of 2025. Source
  • First-quarter placements and validations: In the first quarter the company placed six systems and validated five, against three placements and nine validations a year earlier.
  • 200th Growth Direct system placed: The release calls the 200th Growth Direct system placed globally a significant milestone. Source
  • Deferred revenue above year-end level: Deferred revenue was $5.5 million at June 30, 2026, against $4.7 million at December 31, 2025. Source

Costs and operating expenses

  • Operating expenses rose 8.9%: Total operating expenses were $13.5 million, against $12.4 million a year earlier. Source
  • G&A grew fastest among expense lines: General and administrative rose 11.3%, sales and marketing 10.3% and research and development 3.2%, each against the second quarter of 2025. Source
  • Cost of revenue declined 2.1%: Total cost of revenue was $6.8 million, down from $7.0 million a year earlier, while revenue rose 10.9%. Source

“As we look to the second half of 2026, we remain encouraged by strong customer engagement, continued momentum in multi-system and enterprise deployment opportunities, and an expanding contribution from our collaboration with MilliporeSigma.”

Robert Spignesi, President and CEO

Gross margin and pricing

  • Gross margin reached 15.0%: Gross margin was $1.2 million, or 15.0%, against $0.3 million or 3.8% a year earlier. The release calls it a quarterly record. Source
  • Margin up from first quarter: First-quarter gross margin was 4.6%, so the second-quarter rate was about 10.4 percentage points higher.
  • Six-month gross margin rose: Six-month gross margin was $1.6 million, against $0.7 million in the first half of 2025. Source

Cash, debt and balance sheet

  • Cash and investments near $20 million: Cash, equivalents and short-term investments were about $20 million at June 30, down from about $23 million at March 31, a figure that included restricted cash. Source
  • Interest expense increased sharply: Interest expense was $646 thousand in the quarter, against $12 thousand a year earlier. Source
  • Receivables rose from year-end: Accounts receivable were $5.5 million at June 30, up from $3.1 million at December 31, 2025, and inventory was $18.9 million. Source
  • Stockholders' equity declined: Total stockholders' equity was $17.7 million at June 30, against $20.4 million at March 31 and $33.2 million at December 31, 2025. Source
  • Weighted share count increased: Weighted average basic and diluted shares were 48.3 million, against 44.6 million in the second quarter of 2025. Source

Strategy, collaboration and industry

  • Collaboration contribution expected to grow: Management said the MilliporeSigma collaboration is expected to make an expanding contribution in the second half of 2026. Source
  • Industry tailwinds cited: Management cited increased automation adoption and ongoing US reshoring and biomanufacturing capacity expansion as tailwinds. Source
  • Enterprise deployment talks ongoing: The first-quarter release said management was increasingly engaged with customers on enterprise-level deployments of the Growth Direct platform.

Coming up, as management said on 7 August 2026

  • European Growth Direct Day in October: MilliporeSigma hosts a European Growth Direct Day in October 2026 for customer engagement, education and pipeline development. Source
  • Full-year targets and 2027 momentum: Management said it believes it is well positioned to achieve full-year objectives and enter 2027 with positive momentum. Source

Figures management reported

FigureReported
Growth Direct systems placed, second quarter 2026 Source4
Customer system validations, second quarter 2026 Source9
Growth Direct systems placed, cumulative Source200th system placed globally
Consumable revenue growth, year-over-year Sourcemore than 20%
Recurring revenue share of total revenue Source63%

Earlier plans management reported on

  • Not stated: Management said the quarter reflects continued execution against priorities outlined at the beginning of the year. Source
  • Not stated: Management said it believes the company is well positioned to achieve its full-year objectives. Source
  • Not stated: Management linked the record second-quarter gross margin to progress on its margin expansion initiatives. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.